Atherosclerosis risk in women with polycystic ovarian syndrome: it’s not just the comorbidities

• by Katharine A Bate, Gemma A Figtree

• December 17, 2025

FDA Approves First Oral PCSK9 Inhibitor

Merck reported placebo-adjusted LDL-C reductions of 56% and 59% at week 24 in two phase 3 CORALreef trials supporting the approval.

• by Kathryn Wighton

• July 16, 2026

• 2 min

FDA Approves New Iohexol Vials

The approval includes additional 300 mg iodine/mL and 350 mg iodine/mL vial presentations.

• by Kathryn Wighton

• July 17, 2026

• 2 min

CKM staging faces an early vascular test

Investigators examined Life’s Essential 8 scores and carotid ultrasonography measures across cardiovascular-kidney-metabolic stages in 1,283 young adults.

• by Kathryn Wighton

• September 8, 2026

• 3 min